

News

RCGP Alliance of Primary Care Societies Update

We are pleased to announce that the Primary Care Women's Health Forum have been accepted in to the RCGP Alliance of Primary Care Societies, which brings primary care organisations together to work with the RCGP on topics that span the breadth of general practice.

PCWHF Annual Conference

Registration:

The focus at our annual conference will be on 'Keeping Women's Healthcare on the agenda' and boasts an impressive line-up of key note speakers and a powerful agenda, which should prove both thought-provoking and beneficial for all those attending. The agenda has been designed to be relevant for healthcare professionals working in a primary care setting.

The conference will be held at The Cavendish Conference Centre, London on Thursday 10th October 2013.

Delegates will be eligible to gain up to 5 hours of CPD and reflective learning.

To view the agenda and to book your tickets, please visit the conference website:
<http://www.events4healthcare.com/PCWHFmeeting.html>

Best Practice Award

We will once again invite applications for the Best Practice Award. This award recognises best practice in Women's Health in Primary Care and will be assessed and awarded at the conference.

The deadline for submissions is Friday 30th August 2013. To avoid missing out, please visit the website and submit your abstract today!

For further information and an application form please [Click Here](#)

GP Hot Topics

Primary Care Women's Health Forum and Events 4 Healthcare are delighted to be

coming together to bring to you a series of workshops specifically designed for GPs, on a variety of therapy areas.

These workshops will assist GPs to resolve specific patient issues by using case studies on a variety of patient types in a particular therapy area. Five hours of CPD are available from this day. Feedback from the last event included:

- “All the sessions had practical “take home” messages”
- “All sessions were informative; this was an excellent day, very enjoyable and interactive”
- “Very informative, good coverage of the relevant subjects”
- “What’s new in Women’s Health was very valuable and well presented”
- “Dr Connolly is fantastic! Course was relevant to general practice with all lectures designed to answer questions for GPs”

Women's Health

- Wednesday 16th October, London
- Wednesday 27th November, Manchester



For more information please [Click Here](#)

New Product Available - Zoely®

Zoely® is the first monophasic COC regimen with 1.5 mg estradiol (E2) in combination with 2.5mg norgestrel acetate (NOMAC). It has a reduced hormone free interval in a 24/4 regimen.

E2 is chemically identical to 17β-estradiol, an endogenous estrogen which has low bioavailability. It has reduced impact on metabolic and hepatic parameters compared with ethinyl-estradiol (EE) which means more favourable effect on lipids and reduced impact on markers of hemostasis.

NOMAC is derived from 19-norprogesterone and has an anti-estrogenic activity and mild anti-androgenic effects. This effect prevents endometrial breakdown which potentially delivers an acceptable bleeding profile.

There have not been any comparative trials but the anticipation is that E2 based oral contraceptives may have reduced risk of thromboembolic events but until further studies are completed and reported use of Zoely is restricted to women who can safely use the EE regimens, refer UKMEC.

Monthly costs £5.50

Please click below to view the Faculty Statement



New Product Available - Sanyana Press®

Sanyana Press® contains 104mg Medroxyprogesterone Acetate in 0.65ml suspension in a format licensed for subcutaneous use. It is given every 13 weeks +/- 7 days.

It is supplied in a single-dose pre-filled injector and is injected subcutaneously into the anterior thigh or anterior abdomen.

It is not currently licensed for self administration but in trials this has been found to be feasible and acceptable to women.

Unit price for NHS use is £6.90

Please click below to view the Faculty Statement



EMA Review of Dianette®

The recent review of use of co-cyprindiol products by the European Medicines Agency has addressed the concerns about the risks of thrombosis associated with their use. The incidence of VTE in women using co-cyprindiol products (Dianette®) is 1.5-2 times higher than that found in women using levo-norgestrel-containing combined pills.

FSRH guidance advises that although co-cyprindiol can be used for contraception it should not be used solely for this purpose and women being prescribed this product should be warned of the increased thrombotic risk. And it remains important to prescribe this product only to those women who fulfil the safety criteria for use of oestrogen containing contraceptives as recommended by the UKMEC.

Please click below to view the Faculty Statement



British Menopause Society Women's Health Meetings 2013

The BMS autumn meeting programme kicks off on Wednesday 4th September 2013 with the Scottish Women's Health Meeting to be held in East Kilbride, Glasgow. One day meetings will follow throughout the country over the autumn months, all aimed at providing education for Primary and Secondary Care clinicians in the field of women's health.

Who should attend?

Academics and students; Dietitians; GPs; Gynaecologists; Nutritionists; Pharmacists; Physiotherapists; Practice Nurses; Specialist Nurses and GP & O & G trainees.

Accreditation: 6 hours CME accredited by the Faculty of Sexual and Reproductive Healthcare (FSRH).

For more information, please contact Kate Ellis on **01628 890 199** or go to the BMS website www.thebms.org.uk.

Procurement, patient choice and competition

This guidance from Monitor illustrates how the NHS (Procurement, Patient Choice and Competition) Regulations 2013 might apply to six hypothetical case scenarios. The first scenario uses the joint commissioning of a sexual health service as the illustrative example. Click for more information and to access the guidance.

[>Hypothetical case scenarios – Procurement, Patient Choice and Competition Regulations | News, events & publications | Monitor](#)
[>Case scenarios](#)

Nearly half a million new sexual infections in 2012

New sexually transmitted infection (STI) diagnoses rose by 5% in 2012, according to data published by Public Health England (PHE) earlier this month. Much of this is due to improved data collection, however, continuing high rates in England suggest too many people are still putting themselves at risk through unsafe sex, especially young heterosexual adults and men who have sex with men (MSM). Click below for the most recent PHE Health Protection Report.

[>Health Protection Report | Infection Reports | 2013](#)

Quarterly conceptions for women aged under 18 : Q1 2012

At the end of last month the Office for National Statistics (ONS) published quarterly under 18 conception data by Local Authority area for quarter 1, 2012. Click below for access to the relevant data tables.

[>Release Edition Reference Tables](#)

BHIVA hepatitiscoinfection guidelines web consultation

The 2013 British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis viruses are open for consultation until 1 July. The purpose of these is to provide guidance on best clinical practice in the treatment and management of adults with HIV and viral hepatitis coinfection. Further information on the scope of the guidelines and a copy of the consultation version of the guidelines is available from the BHIVA website or by clicking the links below.

[>BHIVA - BHIVA hepatitis guideline consultation open until 1 July 2013](#)
[>Guideline](#)



Please visit our **new website**, where new members can also **join the forum**.